- Mizuho Securities has increased its price target for Medtronic to $115, signaling strong confidence in the medical technology giant’s future and a potential upside of 24.76%.
- The company reported robust first-quarter results, with quarterly earnings of $1.45 per share and sales of $9.76 billion, both exceeding analyst expectations.
- Medtronic is strategically expanding through a $700 million partnership with Cornerstone Robotics and has raised its fiscal 2027 adjusted EPS outlook to $5.94 to $6.00, alongside increased organic revenue growth projections.
Medtronic (NYSE: MDT) is a global medical technology company that develops therapies to treat a wide range of chronic diseases. Its business includes cardiovascular devices, surgical tools, and diabetes care products. An analyst from Mizuho Securities, Anthony Petrone, has raised the price target for Medtronic to $115, suggesting confidence in the company’s future and its position in the competitive healthcare sector.
This new price target implies a potential upside of approximately 24.76% from the stock’s trading price of $92.18 when the target was announced. The analyst’s positive outlook is supported by the company’s recent strong stock performance and strategic initiatives that point toward continued growth across its business segments, reinforcing its market outlook.
Medtronic’s first-quarter results exceeded expectations, showcasing strong financial health. The company reported quarterly earnings of $1.45 per share, which is higher than the analyst consensus estimate of $1.39 per share. Sales for the quarter also beat forecasts, coming in at $9.76 billion compared to the estimated $9.55 billion, highlighting robust revenue growth in its medical devices portfolio.
Following these strong results, Medtronic raised its financial outlook, reflecting an optimistic investment analysis. The company now expects its fiscal 2027 adjusted earnings per share (EPS) to be in the range of $5.94 to $6.00. It also increased its organic revenue growth forecast to a new range of 7.25% to 7.75%, indicating sustained expansion in the medical technology market.
A significant development is the company’s new $700 million strategic partnership with Cornerstone Robotics. This collaboration is designed to expand the global use of Medtronic’s Sentire Surgical System. As highlighted by Zacks, this move, along with broad-based growth, contributed to the positive investor sentiment and strengthens Medtronic’s market leadership in surgical innovation.
